Sanofi (NASDAQ:SNY) Shares Bought by Keystone Financial Services

Keystone Financial Services increased its stake in Sanofi (NASDAQ:SNY) by 2.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,883 shares of the company’s stock after buying an additional 278 shares during the quarter. Keystone Financial Services’ holdings in Sanofi were worth $670,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SNY. Strategic Financial Concepts LLC acquired a new position in Sanofi in the 4th quarter worth $667,000. Allworth Financial LP boosted its holdings in Sanofi by 28.4% in the fourth quarter. Allworth Financial LP now owns 6,524 shares of the company’s stock valued at $336,000 after purchasing an additional 1,443 shares during the last quarter. V Square Quantitative Management LLC grew its stake in Sanofi by 30.6% during the 4th quarter. V Square Quantitative Management LLC now owns 13,557 shares of the company’s stock valued at $657,000 after purchasing an additional 3,179 shares in the last quarter. McClarren Financial Advisors Inc. increased its holdings in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after purchasing an additional 543 shares during the last quarter. Finally, Van ECK Associates Corp raised its position in shares of Sanofi by 18.1% in the 4th quarter. Van ECK Associates Corp now owns 662,762 shares of the company’s stock valued at $31,965,000 after purchasing an additional 101,726 shares in the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $60.00.

Sanofi Stock Up 0.9 %

Shares of NASDAQ:SNY opened at $54.50 on Monday. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97. The company’s fifty day moving average is $50.30 and its two-hundred day moving average is $52.45. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.74 and a current ratio of 1.46. The stock has a market capitalization of $138.31 billion, a price-to-earnings ratio of 21.89, a price-to-earnings-growth ratio of 0.99 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. Equities analysts anticipate that Sanofi will post 4.36 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.